Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...

Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...

EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.

AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, and Illumina are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks represent ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

AI names and growth stocks have stumbled in early 2025. 2024’s big stock market winners are among the worst performers in recent weeks. AI stocks have plunged double digits amid a wave of challenging ...

Vertex Pharmaceuticals has outperformed the broader healthcare sector over the past year. Despite a 6.3% drop from its ...